del Nido心脏停搏液在成人心脏手术中的应用:一项前瞻性随机试验
这项前瞻性随机对照试验将首次接受冠状动脉旁路移植术(CABG)、瓣膜或CABG/瓣膜手术且需体外循环(CPB)的成人患者随机分配至del Nido心脏停搏液组(n=48)或全血心脏停搏液组(n=41),评估心肌保护效果。结果显示两组CPB时间和主动脉阻断时间无显著差异,del Nido组自主心律恢复率较高(97.7% vs 81.6%;P=.023)、需要正性肌力支持的患者较少(65.1% vs 84.2%;P=.050),但均未达预设显著性水平(P<.001);肌钙蛋白I升高幅度在del Nido组较小(P=.040),同样未达统计学显著。作者认为del Nido心脏停搏液在常规成人病例中可能安全、临床结局相当并可简化手术流程。
要点
- del Nido组自主心律恢复率97.7% vs 全血组81.6%(P=.023),未达预设α P<.001。
- del Nido组需正性肌力支持65.1% vs 全血组84.2%(P=.050),未达统计学显著。
- del Nido组肌钙蛋白I升高幅度较小(P=.040),但未达统计学显著。
核心结论
- 证据提示del Nido心脏停搏液用于常规成人病例可能安全、临床结局相当并可简化手术流程。
- 肌钙蛋白变化趋势应进一步研究,因其可能提示del Nido溶液具有更优的心肌保护作用。
研究设计与样本
- 前瞻性随机对照试验,纳入首次接受CABG、瓣膜或CABG/瓣膜手术且需CPB的成人患者。
- 患者随机分配至del Nido心脏停搏液组(n=48)或全血心脏停搏液组(n=41)。
- 主要结局评估心肌保护,肌钙蛋白I在基线、CPB终止后2小时、心血管重症监护室入住后12和24小时测量。
- α设定为P<.001。
主要发现
- 两组术前特征相似,包括年龄、Society of Thoracic Surgeons风险评分、CABG和瓣膜手术。
- CPB时间97 vs 103分钟(P=.288),主动脉阻断时间70 vs 83分钟(P=.018)。
- del Nido组自主心律恢复率97.7% vs 全血组81.6%(P=.023)。
- del Nido组需正性肌力支持的患者65.1% vs 全血组84.2%(P=.050)。
- del Nido组肌钙蛋白I升高幅度较对照组小(P=.040),但未达统计学显著。
临床怎么用
- 作者认为del Nido心脏停搏液用于常规成人病例可能安全、临床结局相当并可简化手术流程。
- 作者认为肌钙蛋白变化趋势应进一步研究,因其可能提示del Nido溶液具有更优的心肌保护作用。
局限性
- 肌钙蛋白变化趋势应进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The del Nido cardioplegia solution has been used extensively in congenital heart surgery for more than 20 years and more recently for adults. This randomized controlled trial examined whether expanding this technique to adult cardiac surgery confers benefits in surgical workflow and clinical outcome compared with blood-based cardioplegia. METHODS: Adult first-time coronary artery bypass grafting (CABG), valve, or CABG/valve surgery patients requiring cardiopulmonary bypass (CPB) were randomized to del Nido cardioplegia (n = 48) or whole blood cardioplegia (n = 41). Primary outcomes assessed myocardial preservation. Troponin I was measured at baseline, 2 hours after CPB termination, 12 and 24 hours after cardiovascular intensive care unit admission. Alpha was set at P < .001. RESULTS: Preoperative characteristics were similar between groups, including age, Society of Thoracic Surgeons risk score, CABG, and valve procedures. There was no significant difference on CPB time (97 vs 103 minutes; P = .288) or crossclamp time (70 vs 83 minutes; P = .018). The del Nido group showed higher return to spontaneous rhythm (97.7% vs 81.6%; P = .023) and fewer patients required inotropic support (65.1% vs 84.2%; P = .050), but did not reach statistical significance. Incidence of Society of Thoracic Surgeons-defined morbidity was low, with no strokes, myocardial infarctions, renal failure, or operative deaths. For del Nido group patients, troponin levels did not increase as much as for control patients (P = .040), but statistical significance was not reached. CONCLUSIONS: Evidence from this study suggests del Nido cardioplegia use in routine adult cases may be safe, result in comparable clinical outcomes, and streamline surgical workflow. The trend for troponin should be investigated further because it may suggest superior myocardial protection with the del Nido solution.
引用
- Ad N, Holmes SD, Massimiano PS, et al. The use of del Nido cardioplegia in adult cardiac surgery: A prospective randomized trial. J Thorac Cardiovasc Surg. 2017. PMID: 29246552. doi:10.1016/j.jtcvs.2017.09.146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。